Pfizer Ends Asenapine Collaboration With Organon
This article was originally published in The Pink Sheet Daily
Executive Summary
Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.